8.50
+0.5(+6.25%)
Currency In GBp
Address
Dominion Way
Worthing, BN14 8SA
United Kingdom of Great Britain and Northern Ireland
Phone
44 1903 844 700
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
612
First IPO Date
October 11, 2004
| Name | Title | Pay | Year Born |
| Mr. Manuel Llobet | Chief Executive Officer & Executive Director | 484,506 | 1965 |
| Dr. Shaun Antony Furlong | Chief Financial Officer & Executive Director | 207,931 | 1976 |
| Ms. Sue Baker | Head of Human Resources | 0 | N/A |
| Simon Piggott | Head of Clinical Science | 0 | N/A |
| Mr. Matthew Heath | Principal Scientist | 0 | N/A |
| Dr. Murray Skinner | Chief Scientific Officer | 0 | N/A |
| Mr. Russell Picket | Group Financial Controller | 0 | N/A |
| Karley Charlotte Mouatt Cheesman | Company Secretary | 0 | N/A |
| Alan Bullimore | Head of Communication & Market Development | 0 | N/A |
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.